Recipharm and LIDDS have signed an exclusive collaboration for the scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS prostate cancer treatment. The agreement plays part in the upcoming Phase IIb study planned to start in 2016. Recipharm has also invested SEK 5 million in a private placement, becoming the third largest shareholder of LIDDS.   “LIDDS’ technology platform is highly interesting as it potentially can be used for other, already approved therapies ...